Cell therapy company AbelZeta Pharma has announced an agreement with AstraZeneca (LSE: AZN) to co-develop a new CAR T-cell therapy in hepatocellular carcinoma (HCC).
The candidate, C-CAR031, is an autologous, armored GPC3-targeting immunotherapy.
Formerly known as Cellular Biomedicine Group, AbelZeta is a Sino-American firm with a footprint in Maryland, USA, and Shanghai, China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze